Description:

Report Summary

"Filariasis- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), Japan

Study Period: 2016-2028

Filariasis Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Filariasisin the US, Europe, and Japan are also provided in the report.

Filariasis Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes into account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Filariasis Product Profiles & Analysis

This part of the Filariasis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Filariasis Market Outlook

The Filariasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Filariasis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs, patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Filariasis Report Insights

Patient Population in Filariasis

Therapeutic Approaches in Filariasis

Filariasis Pipeline Analysis

Filariasis Market Size and Trends

Filariasis Market Opportunities

Impact of upcoming Therapies in Filariasis

Filariasis Report Key Strengths

10 Year Forecast

‘MM’ Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Filariasis Report Assessment

Current Treatment Practices in Filariasis

Unmet Needs in Filariasis

Detailed Filariasis Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Filariasis market

Organize sales and marketing efforts by identifying the best opportunities for Filariasis market

To understand the future market competition in the Filariasis market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents

1 Key Insights

2 Filariasis Market Overview at a Glance
   • 2.1 Market Share (%) Distribution of Filariasis in 2018
   • 2.2 Market Share (%) Distribution of Filariasis in 2028

3 Filariasis: Disease Background and Overview
   • 3.1 Introduction
   • 3.2 Symptoms
   • 3.3 Etiology
   • 3.4 Risk Factor
   • 3.5 Pathophysiology
   • 3.6 Diagnosis
   • 3.7 Treatment

4 Epidemiology and Patient Population
   • 4.1. Key Findings
   • 4.2. Total Prevalent/Incident Patient Population of Filariasis in 7MM
   • 4.3. Total Prevalent Patient Population of Filariasis in 7MM – By Countries

5 Epidemiology of Filariasis by Countries (2016-2028)
   • 5.1 United States: Epidemiology (2016-2028)
     • 5.1.1 Assumptions and Rationale
     • 5.1.2 Prevalent/Incident Cases of Filariasis in the United States
     • 5.1.3 Sub-Type Specific cases of Filariasis in the United States
     • 5.1.4 Sex: Specific Cases of Filariasis in the United States
     • 5.1.5 Diagnosed Cases of Filariasis in the United States
     • 5.1.6 Treatable Cases of Filariasis in the United States
     • 5.2 EU5 Countries
       • 5.2.1 Germany
         • 5.2.1.1 Assumptions and Rationale
         • 5.2.1.2 Prevalent/Incident Cases of Filariasis in the Germany
         • 5.2.1.3 Sub-Type Specific cases of Filariasis in the Germany
         • 5.2.1.4 Sex: Specific Cases of the Filariasis in the Germany
         • 5.2.1.5 Diagnosed Cases of the Filariasis in the Germany
         • 5.2.1.6 Treatable Cases of the Filariasis
       • 5.2.2 France
         • 5.2.2.1 Assumptions and Rationale
         • 5.2.2.2 Prevalent/Incident Cases of the Filariasis in the France
         • 5.2.2.3 Sub-Type Specific cases of Filariasis in the France
         • 5.2.2.4 Sex: Specific Cases of the Filariasis in the France
         • 5.2.2.5 Diagnosed Cases of the Filariasis in the France
         • 5.2.2.6 Treatable Cases of the Filariasis
       • 5.2.3 Italy
         • 5.2.3.1 Assumptions and Rationale
         • 5.2.3.2 Prevalent/Incident Cases of the Filariasis in the Italy
         • 5.2.3.3 Sub-Type Specific cases of Filariasis in the Italy
         • 5.2.3.4 Sex: Specific Cases of the Filariasis in the Italy
         • 5.2.3.5 Diagnosed Cases of the Filariasis in the Italy
         • 5.2.3.6 Treatable Cases of the Filariasis
       • 5.2.4 Spain
         • 5.2.4.1 Assumptions and Rationale
         • 5.2.4.2 Prevalent/Incident Cases of the Filariasis in the Spain
         • 5.2.4.3 Sub-Type Specific cases of Filariasis in the Spain
         • 5.2.4.4 Sex: Specific Cases of the Filariasis in the Spain
         • 5.2.4.5 Diagnosed Cases of the Filariasis in the Spain
         • 5.2.4.6 Treatable Cases of the Filariasis
       • 5.2.5 United Kingdom
         • 5.2.5.1 Assumptions and Rationale
         • 5.2.5.2 Prevalent/Incident Cases of the Filariasis in the United Kingdom
         • 5.2.5.3 Sub-Type Specific cases of Filariasis in the United Kingdom
         • 5.2.5.4 Sex: Specific Cases of the Filariasis in the United Kingdom
         • 5.2.5.5 Diagnosed Cases of the Filariasis in the United Kingdom
         • 5.2.5.6 Treatable Cases of the Filariasis
       • 5.2.6 Japan
         • 5.2.6.1 Assumptions and Rationale
         • 5.2.6.2 Prevalent/Incident Cases of the Filariasis in Japan
         • 5.2.6.3 Sub-Type Specific cases of Filariasis in Japan
         • 5.2.6.4 Sex: Specific Cases of the Filariasis in Japan
         • 5.2.6.5 Diagnosed Cases of the Filariasis in Japan
         • 5.2.6.6 Treatable Cases of the Filariasis

6 Current Treatment & Medical practices
   • 6.1 Treatment Algorithm
   • 6.2 Treatment Guidelines

7 Unmet Needs

8 Marketed Product
   • 8.1 Drug A: Company 1
     • 8.1.1 Drug Description
     • 8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile
8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile
8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile
8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile
8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile
8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile
8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile
8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile

9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company
9.2.1 Emerging Drug A: Company 29
9.2.1.1 Other Development Activities
9.2.1.2 Clinical Development
9.2.1.3 Clinical Trials Information
9.2.1.4 Safety and Efficacy
9.2.1.5 Advantages and Disadvantages
9.2.1.6 Product Profile
9.2.2 Emerging Drug B: Company 30
9.2.2.1 Other Development Activities
9.2.2.2 Clinical Development
9.2.2.3 Clinical Trials Information
9.2.2.4 Safety and Efficacy
9.2.2.5 Advantages and Disadvantages
9.2.2.6 Product Profile
9.2.3 Emerging Drug C: Company 31
9.2.3.1 Other Development Activities
9.2.3.2 Clinical Development
9.2.3.3 Clinical Trials Information
9.2.3.4 Safety and Efficacy
9.2.3.5 Advantages and Disadvantages
9.2.3.6 Product Profile
9.2.4 Emerging Drug D: Company 32
9.2.4.1 Other Development Activities
9.2.4.2 Clinical Development
9.2.4.3 Clinical Trials Information
9.2.4.4 Safety and Efficacy
9.2.4.5 Advantages and Disadvantages
9.2.4.6 Product Profile
9.2.5 Emerging Drug E: Company 33
9.2.5.1 Other Development Activities
9.2.5.2 Clinical Development
9.2.5.3 Clinical Trials Information
9.2.5.4 Safety and Efficacy
9.2.5.5 Advantages and Disadvantages
9.2.5.6 Product Profile

10 7MM Market Analysis
   10.1 7MM Market Size of Filariasis
   10.2 7MM Percentage Share of Drugs Marketed for Filariasis
   10.3 7MM Market Sales of Filariasis by Products

11 The United States Market Outlook
   11.1 Market Size of Filariasis in United States
   11.2 Percentage Share of Drugs Marketed for Filariasis in United States
   11.3 Market Sales of Filariasis by Products in United States
   11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 Countries Market Outlook
   12.1 Market Size of Filariasis in EU5
   12.2 Market Size of Filariasis in Germany
   12.2.1 Market Size of Filariasis in Germany
   12.2.2 Percentage Share of Drugs Marketed for Filariasis in Germany
   12.2.3 Market Sales of Filariasis by Products in Germany
   12.2.4 Analysis of Upcoming Therapies and Impact on the Market
   12.3 Market Size of Filariasis in France
   12.3.1 Market Size of Filariasis in France
   12.3.2 Percentage Share of Drugs Marketed for Filariasis in France
   12.3.3 Market Sales of Filariasis by Products in France
   12.3.4 Analysis of Upcoming Therapies and Impact on the Market
   12.4 Market Size of Filariasis in Italy
   12.4.1 Market Size of Filariasis in Italy
   12.4.2 Percentage Share of Drugs Marketed for Filariasis in Italy
   12.4.3 Market Sales of Filariasis by Products in Italy
   12.4.4 Analysis of Upcoming Therapies and Impact on the Market
   12.5 Market Size of Filariasis in Spain
   12.5.1 Market Size of Filariasis in Spain
   12.5.2 Percentage Share of Drugs Marketed for Filariasis in Spain
   12.5.3 Market Sales of Filariasis by Products in Spain
   12.5.4 Analysis of Upcoming Therapies and Impact on the Market
   12.6 Market Size of Filariasis in United Kingdom
   12.6.1 Market Size of Filariasis in United Kingdom
   12.6.2 Percentage Share of Drugs Marketed for Filariasis in United Kingdom
   12.6.3 Market Sales of Filariasis by Products in United Kingdom
   12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 The Japan Market Outlook
   13.1 Market Size of Filariasis in Japan
   13.2 Percentage Share of Drugs Marketed for Filariasis in Japan
   13.3 Market Sales of Filariasis by Products in Japan
   13.4 Analysis of Upcoming Therapies and Impact on the Market

14 Cost Analysis of Filariasis
15 Generic Competition in Filariasis Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
   18.1 Methodology/Research Approach
   18.2 Data Source
   18.2.1 Secondary Sources